Celldex Therapeutics’ (CLDX) Overweight Rating Reiterated at Cantor Fitzgerald

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a note issued to investors on Monday, Benzinga reports. They currently have a $67.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 59.37% from the stock’s previous close.

A number of other equities analysts have also weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Monday, August 12th. Wells Fargo & Company raised their target price on shares of Celldex Therapeutics from $35.00 to $37.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. Wolfe Research assumed coverage on shares of Celldex Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 price objective on the stock. Finally, Stifel Nicolaus initiated coverage on Celldex Therapeutics in a research note on Tuesday, June 18th. They set a “buy” rating and a $58.00 target price for the company. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $63.83.

Celldex Therapeutics Stock Performance

NASDAQ:CLDX opened at $42.04 on Monday. The stock has a 50-day simple moving average of $37.73 and a 200 day simple moving average of $39.04. Celldex Therapeutics has a 52-week low of $22.11 and a 52-week high of $53.18. The company has a market cap of $2.77 billion, a PE ratio of -14.75 and a beta of 1.56.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. The firm had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $1.13 million. On average, research analysts predict that Celldex Therapeutics will post -2.5 earnings per share for the current fiscal year.

Insider Buying and Selling at Celldex Therapeutics

In other Celldex Therapeutics news, CFO Samuel Bates Martin sold 17,172 shares of the stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $35.42, for a total value of $608,232.24. Following the completion of the transaction, the chief financial officer now directly owns 28,125 shares in the company, valued at $996,187.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, VP Elizabeth Crowley sold 30,000 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $34.87, for a total transaction of $1,046,100.00. Following the completion of the transaction, the vice president now directly owns 9,074 shares in the company, valued at $316,410.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Samuel Bates Martin sold 17,172 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $35.42, for a total value of $608,232.24. Following the transaction, the chief financial officer now owns 28,125 shares of the company’s stock, valued at $996,187.50. The disclosure for this sale can be found here. Corporate insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Celldex Therapeutics

A number of hedge funds have recently made changes to their positions in CLDX. Point72 Asia Singapore Pte. Ltd. bought a new stake in Celldex Therapeutics in the second quarter worth approximately $76,000. Headlands Technologies LLC bought a new stake in Celldex Therapeutics in the first quarter worth approximately $147,000. CANADA LIFE ASSURANCE Co increased its holdings in Celldex Therapeutics by 26.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares in the last quarter. Aigen Investment Management LP bought a new stake in Celldex Therapeutics in the fourth quarter worth approximately $251,000. Finally, Ameritas Investment Partners Inc. increased its holdings in Celldex Therapeutics by 34.3% in the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 1,582 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.